Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Gene Therapy
|
June 8, 2012
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy
J-S Hulot, G Senyei, R J Hajjar
Revue Neurologique
|
May 27, 2015
Clinical implications of neuropharmacogenetics
J-C Corvol, D Devos, J-S Hulot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 19, 2007
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
P Fontana, J-S Hulot, P De Moerloose, et al.
Fundamental & Clinical Pharmacology
|
July 27, 2001
Beta-blocker treatment in heart failure
A Bouzamondo, J S Hulot, P Sanchez, et al.
Intensive Care Medicine
|
September 29, 1999
Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients
D Lichtenstein, J S Hulot, A Rabiller, et al.
La Revue De Medecine Interne
|
March 6, 2007
[New insights and perspectives in the management of dyslipidemia]
F Cohen Aubart, B Hansel, J-S Hulot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 6, 2009
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
C Frére, T Cuisset, B Gaborit, et al.
La Revue De Medecine Interne
|
June 13, 2006
[Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?]
N Costedoat-Chalumeau, Z Amoura, J S Hulot, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|
February 3, 2007
Favorable outcome of IgA nephropathy on antituberculous treatment
L Mercadal, J S Hulot, C Isnard-Bagnis, et al.
The Pharmacogenomics Journal
|
April 12, 2012
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes
S Martis, I Peter, J-S Hulot, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Gene Therapy
|
June 8, 2012
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy
J-S Hulot, G Senyei, R J Hajjar
Revue Neurologique
|
May 27, 2015
Clinical implications of neuropharmacogenetics
J-C Corvol, D Devos, J-S Hulot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 19, 2007
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
P Fontana, J-S Hulot, P De Moerloose, et al.
Fundamental & Clinical Pharmacology
|
July 27, 2001
Beta-blocker treatment in heart failure
A Bouzamondo, J S Hulot, P Sanchez, et al.
Intensive Care Medicine
|
September 29, 1999
Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients
D Lichtenstein, J S Hulot, A Rabiller, et al.
La Revue De Medecine Interne
|
March 6, 2007
[New insights and perspectives in the management of dyslipidemia]
F Cohen Aubart, B Hansel, J-S Hulot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 6, 2009
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
C Frére, T Cuisset, B Gaborit, et al.
La Revue De Medecine Interne
|
June 13, 2006
[Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?]
N Costedoat-Chalumeau, Z Amoura, J S Hulot, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|
February 3, 2007
Favorable outcome of IgA nephropathy on antituberculous treatment
L Mercadal, J S Hulot, C Isnard-Bagnis, et al.
The Pharmacogenomics Journal
|
April 12, 2012
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes
S Martis, I Peter, J-S Hulot, et al.
Page
of 3